Abbott’s Tendyne™ device has secured FDA approval, revolutionizing mitral valve replacement. This minimally invasive system offers a crucial alternative for high-risk patients with severe mitral annular calcification, eliminating the need for open-heart surgery.
Trastuzumab is a monoclonal antibody that has been engineered to attack and block the human epidermal growth factor receptor 2 (HER2), a protein that contributes to cancer cell growth. It is used most frequently to treat HER2-positive breast cancer and HER2-positive gastric cancer. As a targeted agent, trastuzumab has greatly enhanced treatment outcomes for patients with tumors that overexpress HER2. Mechanism of Action Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to the extracellular domain (subdomain IV) of the […]
XTANDI® (enzalutamide), co-developed by Astellas and Pfizer, has shown a significant 30% reduction in risk of death over five years in metastatic hormone-sensitive prostate cancer (mHSPC) patients, marking it as the first androgen receptor inhibitor to demonstrate this long-term survival benefit.
Potentially Groundbreaking Treatment Could Delay or Prevent Progression to Full-Blown Myeloma.
CellCentric has secured $120 million in Series C funding to accelerate clinical development of Inobrodib, its first-in-class oral p300/CBP inhibitor for treating multiple myeloma. The investment will support upcoming Phase II/III trials and global expansion.
The VENTANA MET (SP44) RxDx Assay detects the MET, or c-Met, protein, which is overexpressed in about 25% of advanced NSQ-NSCLC patients with EGFR wild-type.
The creation of these implants is a direct answer to the demands of patients who need primary or revision reconstruction following a mastectomy.
The Food and Drug Administration’s approval of lecanemab, a new Alzheimer’s medication shown in clinical trials to reduce the disease slowly over time.
In a Phase 3 trial, investigational icotrokinra led to 66% of scalp psoriasis patients and 77% of genital psoriasis patients achieving clear or almost clear skin specifically on those affected sites by Week 16.
IQVIA reported $3.829 billion in total revenue for the first quarter that ended on March 31, 2025, a 2.5% increase over the same period in 2024.
